Drug intelligence / Profile preview

FTH-002

Development stage: Unknown
Lead developer: Faeth Therapeutics
Administration: Oral

Overview

FTH-002 is a specially designed amino acid sachet developed by Faeth Therapeutics for use as a dietary intervention in cancer therapy. It is currently under clinical development for rectal cancer and has also been investigated for pancreatic cancer. The product is administered alongside an amino acid-restricted diet, aiming to modulate tumor metabolism as part of the therapeutic approach. As of 2024, FTH-002 is in Phase I clinical trials for rectal cancer.

Beyond the preview

Go deeper on FTH-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FTH-002.

Explore the full profile